Phaseline

Companies › BrightGene New Bio-Medical Technology(Wuxi) Co.Ltd.

BrightGene New Bio-Medical Technology(Wuxi) Co.Ltd.: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Metabolic and endocrine.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
BGM0504 injection
GLP-1 receptor agonist
–Phase 3Overweight or Obesity–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06704581BGM0504 injectionPhase 3Overweight or ObesityMetabolic and endocrineMar 2026

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Xintian Pharmaceutical Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics Orphalan Lumos Pharma Neuvosyn Laboratories

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.